Avalon Capital Management’s Filana Therapeutics FLNA Stock Holding History

Avalon Capital Management’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-4,934	Closed	-$31K	–	96
2017 Q1	$31K	Hold	4,934	–	–	0.02%	81
2016 Q4	$20K	Sell	4,934 -443	-8%	-$2.05K	0.02%	77
2016 Q3	$38K	Hold	5,377	–	–	0.03%	69
2016 Q2	$82K	Hold	5,377	–	–	0.06%	69
2016 Q1	$84K	Buy	5,377 +715	+15%	+$9.25K	0.07%	70
2015 Q4	$57K	Hold	4,662	–	–	0.05%	64
2015 Q3	$60K	Hold	4,662	–	–	0.06%	57
2015 Q2	$56K	Hold	4,662	–	–	0.05%	63
2015 Q1	$62K	Sell	4,662 -86	-2%	-$1.16K	0.05%	62
2014 Q4	$67K	Sell	4,748 -10,957	-70%	-$190K	0.05%	61
2014 Q3	$430K	Sell	15,705 -129	-0.8%	-$3.92K	0.36%	58
2014 Q2	$637K	Hold	15,834	–	–	0.53%	67
2014 Q1	$610K	Sell	15,834 -3,955	-20%	-$140K	0.49%	70
2013 Q4	$673K	Buy	19,789 +11,384	+135%	+$302K	0.57%	54
2013 Q3	$160K	Hold	8,405	–	–	0.16%	83
2013 Q2	$130K	Buy	+8,405	New	+$178K	0.13%	72

Other funds holding FLNA

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Avalon Capital Management's FLNA Position: Q2 2017 in Review

Avalon Capital Management sold out of Filana Therapeutics (FLNA) in Q2 2017, closing a stake of 4,934 shares — an estimated $31K sold.

Avalon Capital Management first reported a position in FLNA in Q2 2013 and held it in 16 quarters. The position peaked at $673K in Q4 2013. 33 funds tracked by Wall St. Rank hold FLNA as of Q2 2017.

Avalon Capital Management reported no remaining Filana Therapeutics position as of Q2 2017 after selling out during the quarter.
Avalon Capital Management sold 4,934 Filana Therapeutics shares in Q2 2017, an estimated $31K.
Avalon Capital Management first reported a position in Filana Therapeutics in Q2 2013 and held it in 16 quarters.
Avalon Capital Management's Filana Therapeutics position peaked at $673K in Q4 2013.
33 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2017.

Based on Avalon Capital Management's 13F filing for Q2 2017, filed 27 Jul 2017.